Skip to main content

Table 2 Characteristics of eligible studies

From: Effect of metformin on anti-mullerian hormone levels in women with polycystic ovarian syndrome: a systematic review and meta-regression analysis of randomized controlled trials with

Author

Publication Year

Country

Study Design

Mean Age

year

Sample Size

intervention

Sample Size

control

Duration of intervention (Weeks)

Dose of intervention (mg/day)

Type of control

Mean BMI

 

Foroozanfard et al.

2017

Iran

Single arm clinical trial

25.3

30

-

8

1500

-

26.1

 

Tomova et al.

2011

Bulgaria

Single arm clinical trial

26.59

13

-

24

2550

-

30.73

 

Sauerbrun-Cutler et al.

2012

USA

Single arm clinical trial

31.5

16

-

12

1500

-

NR

 

Nascimento et al.

2013

Brazil

Single arm clinical trial

26.3

16

-

8

1500

-

29.1

 

Panidis et al.

2010

Greece

Single arm clinical trial

21.07

15

-

24

1700

-

21.56

 

Neagu et al.

2012

Romania

Single arm clinical trial

NR

11

-

8

2550

-

NR

 

Romualdi et al.

2011

Italy

Single arm clinical trial

24.4

28

-

24

1700

-

33.59

 

Piltonen et al.

2005

Finland

Single arm clinical trial

30.6

26

-

24

1500

-

30.1

 

Dursun et al.

2015

Turkey

Single arm clinical trial

15.2

20

-

24

2000

-

30.6

 

Fleming et al.

2005

USA

Single arm clinical trial

30.2

82

-

32

1500/2550

-

37.1

 

Falbo et al.

2010

Italy

Single arm clinical trial

27.4

10

-

48

1700

-

23

 

Wiweko et al.

2017

Indonesia

Randomized clinical trial (parallel)

28.25

20

18

48

1500

100 mg DLBS3233 DLBS3233 is a herbal medicine produced in Indonesia

28.02

 

Tagliaferri et al.

2017

Italy

Randomized clinical trial (crossover)

25.62

34

34

24

1700

Placebo

32.55

 

Chhabra et al.

2018

India

Randomized clinical trial (parallel)

28.81

35

35

24

1700

Placebo

NR

 

Madsen et al.

2015

Denmark

Randomized clinical trial (crossover)

31.5

45

42

12

1700

Placebo

33.7

 

Fabregues et al.

2010

Spain

Randomized clinical trial (parallel)

32.06

15

15

24

1700

Placebo

25.6

 
  1. BMI: body mass index; N/R: not reported
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us